David Steenburg
Overview
David Steenburg is a counsel in Crowell & Moring’s Washington, D.C. office, where he practices in the Tax Group. David focuses his practice on transactional tax matters.
Career & Education
- Catholic University of America, Columbus School of Law, J.D.,
cum laude
, 2015 - Grove City College, B.A., cum laude, 2007
- Catholic University of America, Columbus School of Law, J.D.,
- District of Columbia
David's Insights
Client Alert | 6 min read | 07.22.25
The One Big Beautiful Bill Act Expands Favorable QSBS Treatment
On July 4, 2025, President Trump signed into law the One Big Beautiful Bill Act (the “Act”), after it was passed by Congress on July 3, 2025. Notably, the Act made significant and welcome changes from the perspective of startup company stockholders and venture capital investors to the qualified small business stock (“QSBS”) rules set forth in Internal Revenue Code (“Code”) Section 1202. In a nutshell, the changes modernize (by adjusting for inflation) and expand the already favorable tax treatment for QSBS under Code Section 1202. The Act also permanently reinstates elective expensing for qualifying domestic research and experimental expenditures that will likely help more startups in research and capital intensive sectors qualify for favorable QSBS treatment.
Firm News | 1 min read | 07.01.25
Crowell Represents Parsons Corporation in Strategic $89M Acquisition
Client Alert | 3 min read | 11.22.24
Key Takeaways from Crowell & Moring’s 38th Annual Managing Tax Audits and Appeals Seminar
Speaking Engagement | 10.24.24
Insights
David's Insights
Client Alert | 6 min read | 07.22.25
The One Big Beautiful Bill Act Expands Favorable QSBS Treatment
On July 4, 2025, President Trump signed into law the One Big Beautiful Bill Act (the “Act”), after it was passed by Congress on July 3, 2025. Notably, the Act made significant and welcome changes from the perspective of startup company stockholders and venture capital investors to the qualified small business stock (“QSBS”) rules set forth in Internal Revenue Code (“Code”) Section 1202. In a nutshell, the changes modernize (by adjusting for inflation) and expand the already favorable tax treatment for QSBS under Code Section 1202. The Act also permanently reinstates elective expensing for qualifying domestic research and experimental expenditures that will likely help more startups in research and capital intensive sectors qualify for favorable QSBS treatment.
Firm News | 1 min read | 07.01.25
Crowell Represents Parsons Corporation in Strategic $89M Acquisition
Client Alert | 3 min read | 11.22.24
Key Takeaways from Crowell & Moring’s 38th Annual Managing Tax Audits and Appeals Seminar
Speaking Engagement | 10.24.24
